St. Anna Kinderspital GmbH
- Address
- lock Available on a paid plan
Hematologic Malignancies and Leukemia Research
At St. Anna Kinderspital GmbH in Vienna, a major focus is on hematology and oncology, especially acute lymphoblastic leukemia, acute myeloid leukemia, and related lymphoblastic lymphoma studies. These trials are designed to improve treatment effectiveness, refine risk-adapted care, and test newer chemo-immunotherapy and targeted approaches for children and adolescents with newly diagnosed, relapsed, or refractory disease.
- New strategies for acute lymphoblastic leukemia and acute myeloid leukemia
- Research in relapsed and refractory hematologic cancers
- Evaluation of targeted and immune-based treatments to improve outcomes
The site also contributes to studies in Philadelphia chromosome-positive and ABL-class leukemia, with the goal of improving survival while reducing treatment burden.
Pediatric Solid Tumor Trials
Another important research area is neoplasms, with trials focused on neuroblastoma, sarcomas, Ewing sarcoma, rhabdomyosarcoma, and other childhood solid tumors. These studies explore new treatment combinations, better disease control, and ways to improve outcomes in high-risk or relapsed disease.
- Neuroblastoma research, including high-risk and relapsed forms
- Studies in Ewing sarcoma and rhabdomyosarcoma
- Testing novel therapies to strengthen response in difficult-to-treat tumors
The research portfolio includes efforts to compare treatment approaches, support better tumor control, and evaluate therapies that may be more effective for children with advanced disease.
Stem Cell Transplantation and Cellular Therapy
The Stem Cell Transplantation Unit at this hospital is actively involved in trials on hematopoietic stem cell transplantation, graft-versus-host disease, and post-transplant care. These studies aim to improve transplant safety, preserve anti-cancer benefit, and reduce complications for children and young adults with high-risk blood cancers.
- Optimization of HSCT for pediatric leukemia
- Trials in graft-versus-host disease prevention and treatment
- Follow-up studies after CAR T-cell therapy and transplant
The research also examines approaches to improve survival after transplant while lowering treatment-related toxicity and long-term side effects.
Immune Disorders and Rare Pediatric Diseases
The site’s immunology and pediatric research includes trials in immune system diseases and selected rare conditions such as Langerhans cell histiocytosis and PIK3CA-related overgrowth spectrum. These studies seek to improve diagnosis, disease control, and long-term management for children with uncommon and complex disorders.
- Chronic graft-versus-host disease and other immune-related conditions
- Langerhans cell histiocytosis research for better disease control
- Rare disease trials aimed at improving care and understanding of biology
Overall, the research program at St. Anna Kinderspital GmbH combines rare disease expertise with pediatric oncology to support more precise and effective treatment choices.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 110 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 107 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St. Anna Kinderspital GmbH
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| AALL2131/EsPhALL2022, An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitor with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia | Universita Degli Studi Di Milano Bicocca | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 110 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etoposide | 18 | Unknown | 2014-03-27 | 2026-02-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.